Spherix Global Insights Highlights Shifts in PD-1 Inhibitor Adoption at ASCO 2026
Event summary
- Spherix Global Insights presented three abstracts at the ASCO 2026 Annual Meeting, including a poster co-authored with Dr. Kimberly Ku.
- RealTime Dynamix™ research shows increasing adoption of subcutaneous PD-1 inhibitors, particularly in monotherapy settings.
- Pembrolizumab (Keytruda) leads in NSCLC and RCC, while nivolumab (Opdivo) maintains dominance in melanoma.
- Oncologists report limited direct control over brand choice due to institutional or payer-level decisions.
The big picture
Spherix Global Insights' findings at ASCO 2026 underscore the evolving landscape of PD-1 inhibitors, where formulation innovations and cost considerations are reshaping treatment strategies. The shift toward subcutaneous administration highlights operational challenges, while biosimilars introduce new competitive dynamics. These trends reflect broader industry movements toward efficiency and cost-effectiveness in oncology care.
What we're watching
- Adoption Dynamics
- How the shift from intravenous to subcutaneous PD-1 inhibitors will affect market share and treatment protocols.
- Biosimilar Impact
- Whether the growing awareness of PD-1 biosimilars will translate into broader adoption, despite institutional constraints.
- Competitive Shifts
- The pace at which subcutaneous formulations reshape brand preferences across key indications.
Related topics